{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:20:35Z","timestamp":1789471235185,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA040500"],"award-info":[{"award-number":["P30 DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01 DA048172"],"award-info":[{"award-number":["K01 DA048172"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32 MH073553"],"award-info":[{"award-number":["T32 MH073553"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cornell Center for Health Equity"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11606-020-06409-6","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T22:02:37Z","timestamp":1611093757000},"page":"1898-1905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-2839","authenticated-orcid":false,"given":"Shashi N.","family":"Kapadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith L.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas R.","family":"Ziebarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Czarina N.","family":"Behrends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"3","key":"6409_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1360-0443.2007.02090.x","volume":"103","author":"A Gibson","year":"2008","unstructured":"Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103(3):462\u2013468.","journal-title":"Addiction."},{"key":"6409_CR2","first-page":"CD002207","volume":"2","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014(2):CD002207.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6409_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.12307","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. J Rural Health 2019;35(1):108\u2013112.","journal-title":"J Rural Health"},{"issue":"6","key":"6409_CR4","doi-asserted-by":"publisher","first-page":"e196373","DOI":"10.1001\/jamanetworkopen.2019.6373","volume":"2","author":"RL Haffajee","year":"2019","unstructured":"Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. JAMA Netw Open 2019;2(6):e196373.","journal-title":"JAMA Netw Open"},{"issue":"1\u20132","key":"6409_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend 2013;131(1\u20132):23\u201335.","journal-title":"Drug Alcohol Depend"},{"key":"6409_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend 2019;198:80\u201386.","journal-title":"Drug Alcohol Depend"},{"key":"6409_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.socscimed.2019.05.027","volume":"232","author":"EF Madden","year":"2019","unstructured":"Madden EF. Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Soc Sci Med 2019;232:324\u2013331.","journal-title":"Soc Sci Med"},{"key":"6409_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jsat.2019.01.019","volume":"100","author":"D Muthulingam","year":"2019","unstructured":"Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. J Subst Abus Treat 2019;100:18\u201328.","journal-title":"J Subst Abus Treat"},{"key":"6409_CR9","doi-asserted-by":"crossref","unstructured":"Richard EL, Schalkoff CA, Piscalko HM, et al. \u201cYou are not clean until you\u2019re not on anything\u201d: Perceptions of medication-assisted treatment in rural Appalachia. Int J Drug Policy 2020:102704.","DOI":"10.1016\/j.drugpo.2020.102704"},{"issue":"4","key":"6409_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1370\/afm.2099","volume":"15","author":"CHA Andrilla","year":"2017","unstructured":"Andrilla CHA, Coulthard C, Larson EH. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder. Ann Fam Med 2017;15(4):359\u2013362.","journal-title":"Ann Fam Med"},{"key":"6409_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2016.10.005","volume":"74","author":"A Kermack","year":"2017","unstructured":"Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abus Treat 2017;74:1\u20136.","journal-title":"J Subst Abus Treat"},{"key":"6409_CR12","unstructured":"Harm Reduction Coalition. Principles of Harm Reduction. https:\/\/harmreduction.org\/about-us\/principles-of-harm-reduction\/. Accessed Aug 15 2020."},{"key":"6409_CR13","unstructured":"Harm Reduction International. What is harm reduction? 2020; https:\/\/www.hri.global\/what-is-harm-reduction. Accessed Aug 15 2020."},{"issue":"1","key":"6409_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12954-017-0196-4","volume":"14","author":"M Hawk","year":"2017","unstructured":"Hawk M, Coulter RWS, Egan JE, et al. Harm reduction principles for healthcare settings. Harm Reduct J 2017;14(1):70.","journal-title":"Harm Reduct J"},{"key":"6409_CR15","unstructured":"Framework for program evaluation in public health. MMWR Recomm Rep 1999;48(RR\u201311):1\u201340."},{"issue":"6","key":"6409_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s11606-018-4807-x","volume":"34","author":"SE Wakeman","year":"2019","unstructured":"Wakeman SE, Rigotti NA, Chang Y, et al. Effect of Integrating Substance Use Disorder Treatment into Primary Care on Inpatient and Emergency Department Utilization. J Gen Intern Med 2019;34(6):871\u2013877.","journal-title":"J Gen Intern Med"},{"key":"6409_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2019.03.009","volume":"200","author":"BE Payne","year":"2019","unstructured":"Payne BE, Klein JW, Simon CB, et al. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. Drug Alcohol Depend 2019;200:71\u201377.","journal-title":"Drug Alcohol Depend"},{"key":"6409_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","volume":"107","author":"RL Snow","year":"2019","unstructured":"Snow RL, Simon RE, Jack HE, Oller D, Kehoe L, Wakeman SE. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic. J Subst Abus Treat 2019;107:1\u20137.","journal-title":"J Subst Abus Treat"},{"issue":"5","key":"6409_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ajad.12925","volume":"28","author":"CS Lee","year":"2019","unstructured":"Lee CS, Rosales R, Stein MD, et al. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients. Am J Addict 2019;28(5):409\u2013412.","journal-title":"Am J Addict"},{"issue":"1","key":"6409_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13722-017-0072-2","volume":"12","author":"EP Bhatraju","year":"2017","unstructured":"Bhatraju EP, Grossman E, Tofighi B, et al. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract 2017;12(1):7.","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"6409_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/08897077.2018.1443541","volume":"39","author":"MA Bachhuber","year":"2018","unstructured":"Bachhuber MA, Thompson C, Prybylowski A, Benitez JM, Mazzella SM, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus 2018;39(2):167\u2013172.","journal-title":"Subst Abus"},{"issue":"6","key":"6409_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19(6):349\u2013357.","journal-title":"Int J Qual Health Care"},{"key":"6409_CR23","doi-asserted-by":"crossref","unstructured":"Bourgeault IL, Dingwall R, De Vries RG. The SAGE handbook of qualitative methods in health research. Los Angeles: SAGE; 2010.","DOI":"10.4135\/9781446268247"},{"issue":"9","key":"6409_CR24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res 2005;15(9):1277\u20131288.","journal-title":"Qual Health Res"},{"key":"6409_CR25","unstructured":"NVivo Qualitative Data Analysis Software [computer program]. Version 11: QSR International Pty Ltd.; 2017."},{"issue":"1","key":"6409_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/003335490411900109","volume":"119","author":"D Heller","year":"2004","unstructured":"Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep 2004;119(1):32\u201339.","journal-title":"Public Health Rep"},{"key":"6409_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","volume":"161","author":"G Kourounis","year":"2016","unstructured":"Kourounis G, Richards BD, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: Lowering the treatment thresholds. Drug Alcohol Depend 2016;161:1\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"6409_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","volume":"46","author":"J Gryczynski","year":"2014","unstructured":"Gryczynski J, Mitchell SG, Jaffe JH, O'Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients' reasons for cessation of care. J Subst Abus Treat 2014;46(3):356\u2013361.","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"6409_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining Low-threshold Buprenorphine Treatment. J Addict Med 2020;14(2):95\u201398.","journal-title":"J Addict Med"},{"key":"6409_CR30","unstructured":"American Society of Addiction Medicine. National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Chevy Chase, MD: American Society of Addiction Medicine, 2015."},{"key":"6409_CR31","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full document. Rockville, 2018."},{"key":"6409_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jsat.2015.09.004","volume":"61","author":"AJ Accurso","year":"2016","unstructured":"Accurso AJ, Rastegar DA. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence. J Subst Abus Treat 2016;61:74\u201379.","journal-title":"J Subst Abus Treat"},{"issue":"6","key":"6409_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.9740\/mhc.2017.11.271","volume":"7","author":"A Kapuganti","year":"2017","unstructured":"Kapuganti A, Turner T, Thomas CJ. Evaluation of buprenorphine\/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder. Mental Health Clin 2017;7(6):271\u2013275.","journal-title":"Mental Health Clin"},{"issue":"1","key":"6409_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction."},{"issue":"7","key":"6409_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ajad.12288","volume":"24","author":"P Jacobs","year":"2015","unstructured":"Jacobs P, Ang A, Hillhouse MP, et al. Treatment outcomes in opioid dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories. Am J Addict 2015;24(7):667\u2013675.","journal-title":"Am J Addict"},{"issue":"6","key":"6409_CR36","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s11606-019-04943-6","volume":"34","author":"ES Cole","year":"2019","unstructured":"Cole ES, DiDomenico E, Cochran G, et al. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder. J Gen Intern Med 2019;34(6):936\u2013943.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"6409_CR37","first-page":"398","volume":"64","author":"BA Lown","year":"2019","unstructured":"Lown BA, Shin A, Jones RN. Can Organizational Leaders Sustain Compassionate, Patient-Centered Care and Mitigate Burnout? J Healthc Manag 2019;64(6):398\u2013412.","journal-title":"J Healthc Manag"},{"key":"6409_CR38","doi-asserted-by":"crossref","unstructured":"Agarwal SD, Pabo E, Rozenblum R, Sherritt KM. Professional Dissonance and Burnout in Primary Care: A Qualitative Study. JAMA Intern Med 2020.","DOI":"10.1001\/jamainternmed.2019.6326"},{"issue":"4","key":"6409_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/08897077.2016.1181695","volume":"37","author":"M Cosden","year":"2016","unstructured":"Cosden M, Sanford A, Koch LM, Lepore CE. Vicarious trauma and vicarious posttraumatic growth among substance abuse treatment providers. Subst Abus 2016;37(4):619\u2013624.","journal-title":"Subst Abus"},{"key":"6409_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugalcdep.2017.01.015","volume":"174","author":"A Reyre","year":"2017","unstructured":"Reyre A, Jeannin R, Largueche M, Moro MR, Baubet T, Taieb O. Overcoming professionals\u2019 challenging experiences to promote a trustful therapeutic alliance in addiction treatment: A qualitative study. Drug Alcohol Depend 2017;174:30\u201338.","journal-title":"Drug Alcohol Depend"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06409-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06409-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06409-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:50:40Z","timestamp":1744181440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06409-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6409"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06409-6","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"6 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Kapadia has received research grants paid to his institution from Gilead Sciences Inc., unrelated to the current study, for research related to hepatitis C. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}